Alk-Abelló currently offers two ranges of rare allergenic products: the subcutaneous Pangramin Ultra (SCIT) and the SlitOne Ultra in drops form (SLIT). "Since the production of rare allergens is subject to the same stringent regulatory requirements as for the production of common allergens, we have come to the conclusion that in the long run we will not be able to offer several Rare allergen product lines in parallel, "said a spokeswoman. SlitOne Ultra being able to provide more stable and reliable production and delivery, the company's decision was made on the shape of the drop. The Pangramin Ultra product line is discontinued. "Of course, it does not happen overnight," says the manufacturer. Pangramin Ultra follow-up therapies are still available until 2021, so therapies already started can be completed and patients do not break down.
Extinguishing Pangramin Ultra preparations are standardized allergen preparations in the form of a depot for specific immunotherapy. They are used for the causal treatment of allergic diseases of the immediate type, caused by various allergens. These include, for example, allergic rhinitis, allergic conjunctivitis and allergic bronchial asthma, as well as in some cases allergic urticaria.
Treatment with Pangramin Ultra supplements consists of an initial treatment – during which the dose is increased – followed by a follow-up treatment. During the initial treatment, the amount of allergen applied is gradually increased from the initial dose to a maintenance dose. The treatment and administration of Pangramin Ultra are done by a doctor: the injection is strictly subcutaneous. After each injection, the patient should be monitored for at least 30 minutes or according to current medical guidelines.